NEW YORK (GenomeWeb News) – MetaStat today said it has reached two exclusive licensing agreements for the use of alternatively spliced mRNA and protein isoform biomarkers.

The agreements are with the Massachusetts Institute of Technology and its David H. Koch Institute for Integrative Cancer Research at MIT and its department of biology, the Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center. The technology being licensed is for the diagnosis, prognosis, and treatment of metastasis in epithelial solid tumor cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.